Vyome Holdings (HIND) Revenue (2015 - 2026)
Vyome Holdings (HIND) posted Revenue of $26955.0 for Q2 2026, down 14.68% on a QoQ basis from $31591.0 in Q1 2026, and down 46.04% year-over-year from $49954.0 in Q2 2025.
Analysis
Vyome Holdings (HIND) Revenue (2015 - 2026) Analysis & Trends
Vyome Holdings has reported Revenue for 12 years, with the latest figure at $26955.0 in Q2 2026.
- On a quarterly basis, Revenue fell 46.04% year-over-year to $26955.0 in Q2 2026; TTM through Jun 2026 was $129724.0, a 67.12% decrease from a year earlier, with the FY2025 full-year figure at $319714.0, up 24.43% from the prior year.
- Revenue was $26955.0 for Q2 2026 at Vyome Holdings, down from $31591.0 in the prior quarter.
- The five-year high for Revenue was $3.1 million in Q4 2022, with the low at $26955.0 in Q2 2026.
- Average Revenue over 5 years is $1.4 million, with a median of $2.0 million recorded in 2024.
- The sharpest annual moves came in 2023 and 2025: Revenue dropped 6.27% in 2023, then slumped 97.46% in 2025.
- Over 5 years, Revenue stood at $3.1 million in 2022, then sank by 36.27% to $2.0 million in 2023, then tumbled by 96.9% to $61428.0 in 2024, then sank by 40.5% to $36551.0 in 2025, then retreated by 26.25% to $26955.0 in 2026.
- The last three Revenue figures came in at $26955.0 (Q2 2026), $31591.0 (Q1 2026), and $36551.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 10.05 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 7.80 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 3.33 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 4.29 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 1.52 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 145.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.29 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.74 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 1.44 Mn |
| 10 | Vyome Holdings | 14.46 Mn | 6.57 Mn | 11,658.00 | 26,955.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 26,955.00 |
| Mar 31, 2026 | 31,591.00 |
| Dec 31, 2025 | 36,551.00 |
| Sep 30, 2025 | 34,627.00 |
| Jun 30, 2025 | 49,954.00 |
| Mar 31, 2025 | 198,581.00 |
| Dec 31, 2024 | 61,428.00 |
| Sep 30, 2024 | 84,526.00 |
| Jun 30, 2024 | 1.97 Mn |
| Mar 31, 2024 | 1.94 Mn |
| Dec 31, 2023 | 1.98 Mn |
| Sep 30, 2023 | 2.16 Mn |
| Jun 30, 2023 | 2.25 Mn |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 3.11 Mn |
| Sep 30, 2022 | 2.80 Mn |
| Jun 30, 2022 | 2.89 Mn |
| Mar 31, 2022 | 2.44 Mn |
| Sep 30, 2021 | 3.71 Mn |
| Jun 30, 2021 | 3.53 Mn |